Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97332 | 0.98 | SIGMAR1 (0.52) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL96962 | 0.98 | SIGMAR1 (0.52) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL97490 | 0.94 | TDP1 (0.46) | SIGMAR1IDO1FFAR1MAOALMNA | |
| SCHEMBL27373 | 0.94 | IDO1 (0.55) | SIGMAR1IDO1FFAR1MAOALMNA | |
| SCHEMBL5547690 | 0.93 | TDP1 (0.49) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL2961385 | 0.93 | TDP1 (0.49) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL5546766 | 0.93 | TDP1 (0.49) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL5545719 | 0.93 | TDP1 (0.49) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL5537354 | 0.93 | TDP1 (0.49) | SIGMAR1IDO1FFAR1MAPTRXFP1 | |
| SCHEMBL96791 | 0.93 | TDP1 (0.49) | SIGMAR1IDO1FFAR1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049660-A1 | ENOL ETHER PROPERFUME | FIRMENICH SA (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4416125-A1 | ENOL ETHER PROPERFUME | Firmenich SA (CH) | 2024-08-21 | — | — | EP | disclosed |
| CN-118369306-A | Enol ether pro-fragrances | 弗门尼舍有限公司 | 2024-07-19 | — | — | CN | disclosed |
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-3423429-B1 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | UNIV DE MONCTON (CA) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023111006-A1 | ENOL ETHER PROPERFUME | FIRMENICH SA (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-9745294-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744153-B2 | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-4420624-A | ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0088385-A2 | 7-Acylamino-3-cephem-4-carboxylic acid derivatives, processes for the preparation of the same and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-09-14 | — | — | EP | disclosed |
| US-4361701-A | SPECTINOMYCIN ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1982-11-30 | — | — | US | disclosed |
| US-4351771-A | Spectinomycin analogs and methods for the preparation thereof | THE UPJOHN COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| US-4345086-A | ETHERIFICATION, CYCLIZATION, SULFIDING | THE UPJOHN COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
| US-4337347-A | ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| US-4282152-A | Intermediates for preparing spectinomycin and analogs thereof | THE UPJOHN COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
| US-4057550-A | 14,15-DIHYDRO-14-CYANO-EBURNAMENINES, VASODILATION | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-11-08 | — | — | US | disclosed |
| US-4054571-A | Nitrogen-containing polycyclic compounds and a process for the preparation thereof | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SIGMAR1 4091/4885IDO1 2430/4885FFAR1 1292/4885 |
| US-20250049660-A1 | ENOL ETHER PROPERFUME | CYP2E1, ADH5, ECI1 | SIGMAR1 2813/4885IDO1 2923/4885FFAR1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.